Drug Trial Radar · NCT05133336
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
196
Actual
Start
Apr 1, 2022
Primary completion
Apr 30, 2025
Study completion May 7, 2025
Sponsor
- Lead sponsor
- Zydus Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)
Conditions
- Primary Biliary Cholangitis
Interventions
Saroglitazar Magnesium 1 mgDrug
Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment for the entire treatment period up to Week 52.
Saroglitazar Magnesium 2 mgDrug
Subjects randomized to Saroglitazar Magnesium 2 mg arm are switched to Saroglitazar Magnesium 1 mg treatment up to Week 52
PlaceboDrug
Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with biochemical response based on the composite endpoints of ALP and total bilirubinTime frame: From baseline to week 52
Locations
57 sites in 4 countries. Site status is shown where the registry gives one.
Zydus US007
Birmingham, Alabama
Zydus US021
Tucson, Arizona
Zydus US013
Los Angeles, California
Zydus US011
Pasadena, California
Zydus US043
Sacramento, California
Zydus US022
Aurora, Colorado
Zydus US037
New Haven, Connecticut
Zydus US027
Jacksonville, Florida
Zydus US006
Lakewood Rch, Florida
Zydus US005
Miami, Florida
Zydus US028
Sarasota, Florida
Zydus US019
Tampa, Florida
Zydus US020
Marietta, Georgia
Zydus US001
Indianapolis, Indiana
Zydus US034
Iowa City, Iowa
Zydus US036
Marrero, Louisiana
Zydus US023
Rochester, Minnesota
Zydus US030
St Louis, Missouri
Zydus US024
Omaha, Nebraska
Zydus US038
Manhasset, New York
Zydus US035
Rochester, New York
Zydus US002
Charlotte, North Carolina
Zydus US014
Cincinnati, Ohio
Zydus US015
Philadelphia, Pennsylvania
Zydus US004
Houston, Texas
Zydus US042
Houston, Texas
Zydus US031
Murray, Utah
Zydus US016
Charlottesville, Virginia
Zydus US041
Newport News, Virginia
Zydus US039
Richmond, Virginia
Zydus US033
Seattle, Washington
Zydus AR004
Buenos Aires, Argentina
Zydus AR009
Buenos Aires, Argentina
Zydus AR001
Buenos Aires, Argentina
Zydus AR013
Buenos Aires, Argentina
Zydus AR007
Buenos Aires, Argentina
Zydus AR006
Buenos Aires, Argentina
Zydus AR005
Buenos Aires, Argentina
Zydus AR012
Buenos Aires, Argentina
Zydus AR003
Buenos Aires, Argentina
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.